the Effect of Vitamin D on the Serum Thioredoxin, TBP-2, Thioredoxin Reductase, Gene Expression of TBP-2 in Patients With Type II Diabetes

Status

UNKNOWN

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01876563

Enrollment

Registered

2013-06-12

Start date

2012-08-31

Completion date

2014-07-31

Last updated

2013-06-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 Diabetes

Keywords

thioredoxin, TBP-2, thioredoxin reductase, vitamin D, DIABETES

Brief summary

The aim of this study is the comparision between the effects of vitamin D or placebo supplementation for 2 months in serum level of thioredoxin, TBP-2 and thioredoxin reductase activity in patients with type 2 diabetes

Interventions

DIETARY_SUPPLEMENTvitamin D

one tab 4000 IU/day vitamin D

DIETARY_SUPPLEMENTplacebo

one tab per day placebo

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

30 Years to 60 Years

Healthy volunteers

Inclusion criteria

literate, willingness to participation, diabetic patients 30- 60 years old, body mass index in the range 18.5- 35, avoidance of dietary supplements, vitamins and herbal products at least 3 months before and throughout the intervention -

Exclusion criteria

people who have used vitamin D supplements in last 3 months, having chronic renal disease , GI disease, Hepatobilliary diseases, hematological disorders, hypo- or hyperthyroidism, treatment with orlistat or sibutramine for weight loss, pregnancy and lactation, treatment with insulin or Thiazolidinediones, Smokers \-

Design outcomes

Primary

Measure	Time frame
erytrocyte thioredoxin reductase	change from baseline at 2 months
serum total cholesterol	change from baseline at 2 months
serum HDL cholesterol	change from baseline at 2 months
serum triglycerides level	change from baseline at 2 months
fasting plasma glucose	change from baseline at 2 months
serum LDL cholesterol	change from baseline at 2 months
complete blood count (CBC)	change from baseline at 2 months
HbA1c	change from baseline at 2 months
serum insulin	change from baseline at 2 months
serum calcidiol	change from baseline at 2 months
thioredoxin	change from baseline at 2 months
thioredoxin binding protein 2 (TBP-2)	change from baseline at 2 months

Secondary

Measure	Time frame
GENE EXPRESSION OF TBP-2	change from baseline at 2 months

Countries

Iran

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026